美国血液学会关于COVID-19患者抗凝血栓预防的动态指南:执行摘要
美国血液学会(ASH)基于2023年6月前的系统评价,采用GRADE方法制定COVID-19患者抗凝血栓预防的动态指南执行摘要。对COVID-19危重症患者,建议预防强度优于治疗强度、预防强度优于中等强度抗凝;对急性病住院患者,建议预防强度优于中等强度、治疗强度优于预防强度;建议反对出院后抗凝血栓预防。上述条件性推荐基于低或极低证据确定性。
要点
- COVID-19危重症:建议预防强度优于治疗强度抗凝(条件性推荐)
- COVID-19危重症:建议预防强度优于中等强度抗凝(条件性推荐)
- COVID-19急性病:建议预防强度优于中等强度抗凝,治疗强度优于预防强度(条件性推荐)
核心结论
- 对COVID-19危重症患者,专家组发出条件性推荐,建议预防强度优于治疗强度抗凝,并建议预防强度优于中等强度抗凝。
- 对COVID-19急性病患者,专家组发出条件性推荐,建议预防强度优于中等强度抗凝,并建议治疗强度优于预防强度抗凝。
- 专家组发出条件性推荐,建议反对使用出院后抗凝血栓预防。
- 上述条件性推荐基于低或极低证据确定性,凸显针对COVID-19患者开展更多高质量随机对照试验的必要性。
研究设计与样本
- ASH组建了包括患者代表在内的多学科专家组,由麦克马斯特大学Michael G. DeGroote Cochrane Canada和MacGRADE中心支持指南制定,包括执行截至2023年6月的系统评价。
- 专家组根据对临床医生和患者的重要性优先考虑临床问题和结局,并采用GRADE方法评估证据确定性并制定推荐。
- 本文是已发表的3条更新推荐的执行摘要,结束了该指南的动态更新阶段。
主要发现
- 对COVID-19危重症患者,专家组发出条件性推荐,建议预防强度优于治疗强度抗凝。
- 对COVID-19危重症患者,专家组发出条件性推荐,建议预防强度优于中等强度抗凝。
- 对COVID-19急性病患者,专家组发出条件性推荐,建议预防强度优于中等强度抗凝。
- 对COVID-19急性病患者,专家组发出条件性推荐,建议治疗强度优于预防强度抗凝。
- 专家组发出条件性推荐,建议反对使用出院后抗凝血栓预防。
关键数值与推荐
- 对COVID-19危重症患者:条件性推荐,建议预防强度优于治疗强度抗凝。
- 对COVID-19危重症患者:条件性推荐,建议预防强度优于中等强度抗凝。
- 对COVID-19急性病患者:条件性推荐,建议预防强度优于中等强度抗凝。
- 对COVID-19急性病患者:条件性推荐,建议治疗强度优于预防强度抗凝。
- 对出院患者:条件性推荐,建议反对使用出院后抗凝血栓预防。
临床怎么用
- 对COVID-19危重症患者,专家组条件性推荐预防强度优于治疗强度抗凝。
- 对COVID-19危重症患者,专家组条件性推荐预防强度优于中等强度抗凝。
- 对COVID-19急性病患者,专家组条件性推荐预防强度优于中等强度抗凝,并条件性推荐治疗强度优于预防强度抗凝。
- 对出院患者,专家组条件性推荐建议反对使用出院后抗凝血栓预防。
局限性
- 上述条件性推荐基于低或极低证据确定性。
- 原文结论指出,凸显针对COVID-19患者开展更多高质量随机对照试验的必要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19-related critical and acute illness is associated with an increased risk of venous thromboembolism (VTE). These evidence-based recommendations of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about using anticoagulation for thromboprophylaxis for patients with COVID-19-related critical illness; patients with COVID-19-related acute illness; and those being discharged from the hospital, who do not have suspected or confirmed VTE. METHODS: ASH formed a multidisciplinary panel, including patient representatives. The Michael G. DeGroote Cochrane Canada and MacGRADE Centres at McMaster University supported guideline development, including performing systematic reviews (up to June 2023). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess certainty in the evidence and make recommendations. RESULTS: This is an executive summary of 3 updated recommendations that have been published, which concludes the living phase of the guidelines. For patients with COVID-19-related critical illness, the panel issued conditional recommendations suggesting (a) prophylactic-intensity over therapeutic-intensity anticoagulation and (b) prophylactic-intensity over intermediate-intensity anticoagulation. For patients with COVID-19-related acute illness, conditional recommendations were suggested (a) prophylactic-intensity over intermediate-intensity anticoagulation, and (b) therapeutic-intensity over prophylactic-intensity anticoagulation. The panel issued a conditional recommendation suggesting against the use of postdischarge anticoagulant thromboprophylaxis. CONCLUSIONS: These conditional recommendations were made based on low or very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials for patients with COVID-19.
引用
- Siegal DM, Tseng EK, Schünemann HJ, et al. American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary. Blood Adv. 2025. PMID: 39437797. doi:10.1182/bloodadvances.2024014219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。